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24Objective: The study objective was to evaluate the long-term survival of patients with radiographically deter-
mined noninvasive lung adenocarcinomas.
Methods: A prospective, multi-institutional study on image diagnosis to define early (noninvasive) adenocar-
cinomas of the lung (Japan Clinical Oncology Group 0201) has shown that a consolidation/tumor ratio on
thin-section computed tomography 0.25 or less in cT1a (2.0 cm) could be used as a better radiologic criterion
for a noninvasive pathology than a consolidation/tumor ratio 0.50 or less in cT1a-b (3.0 cm). From the prog-
nostic viewpoints, these criteria were evaluated for 545 patients with adenocarcinoma who underwent
lobectomy and lymph node dissection.
Results: The subjects consisted of 233 men and 312 women with a median age of 62 years. The median follow-
up period among overall patients was 7.1 years (range, 0-8.5 years). The overall and relapse-free 5-year survivals
of the overall patients were 90.6% and 84.7%, respectively. When a consolidation/tumor ratio 0.5 or less in
cT1a-b was used as a cutoff, the 5-year overall survivals of radiologic noninvasive (121 patients, 22.2%) and
invasive (424 patients, 77.8%) adenocarcinomas were 96.7% and 88.9%, respectively, and the difference
was statistically significant (P<.001, log-rank test). With the use of a consolidation/tumor ratio 0.25 or less
in cT1a, the 5-year overall survivals of radiologic noninvasive (35 patients, 12.1%) and invasive (254 patients,
87.9%) adenocarcinomas were 97.1% and 92.4%, respectively, and the difference was not statistically
significant (P ¼ .259).
Conclusions: The radiologic criteria of a consolidation/tumor ratio 0.25 or less in cT1a (2.0 cm) and 0.50 in
cT1a-b (3.0 cm) were both able to define a homogeneous group of patients with an excellent prognosis before
surgery. (J Thorac Cardiovasc Surg 2013;146:24-30)Our understanding of the natural history of small, peripheral
adenocarcinomas has greatly progressed.1-5 This
understanding is reflected in the recently revised
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The Journal of Thoracic and Cardiovascular SurgeThis new classification is characterized by the creation/
abandonment of some terminology for early and advanced
adenocarcinomas and by a multidisciplinary approach for
the application of the new classification in a clinical setting.
In particular, the term ‘‘bronchioloalveolar carcinoma’’ is
no longer used, and new concepts have been introduced,
such as adenocarcinoma in situ and minimally invasive
adenocarcinoma. Invasive adenocarcinomas are classified
according to the predominant pattern after comprehensive
histologic subtyping with lepidic, acinar, papillary, micro-
papillary, and solid patterns. The term ‘‘mixed subtype
adenocarcinoma’’ is no longer used.
In this new proposal, the surgical features have been de-
scribed as part of a multidisciplinary approach to the com-
prehensive classification of adenocarcinomas. Especially
for early adenocarcinomas, crucial questions have been
raised, such as ‘‘Is sublobar (limited) resection adequate on-
cological treatment for some early adenocarcinomas?’’ and
‘‘Can computed tomography (CT) be used to select patients
for sublobar resection?’’6,7 The Japan Clinical Oncology
Group (JCOG) conducted a prospective, radiologic study
of thin-section computed tomography (TSCT) to identify
radiologic criteria that predict pathologic noninvasivenessry c July 2013
Abbreviations and Acronyms
CI ¼ confidence interval
CT ¼ computed tomography
C/T ¼ consolidation/tumor
GGO ¼ ground-glass opacity
JCOG ¼ Japan Clinical Oncology Group
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Sin clinical IA lung cancer arising in the periphery of the lung
(JCOG 0201).8 The current study demonstrates the progno-
sis of the patients who are selected for limited sublobar re-
section according to the radiologic criteria for noninvasive
adenocarcinomas. If we believe that patients with noninva-
sive adenocarcinomas may be appropriately treated with
limited sublobar surgical resection instead of lobectomy,
it is crucially important to answer the question, ‘‘Can CT
be used to select candidates for sublobar resection or those
who can benefit from limited sublobar resection?’’
In selecting candidates for sublobar resection for early
lung adenocarcinomas, however, the preoperative, radio-
logic prediction of the degree of invasive growth of the
tumor has been realized to be a crucial point. Because of
the advent of high-resolution CT or TSCT, the radiologic
appearance of adenocarcinomas at various stages has been
described in detail, and the radiology-pathology correlation
has been studied. A localized, nodular lesion characterized
by a low-to-moderate increase in CT density that does not
obscure lung structures, such as the pulmonary artery/vein
and bronchus, is referred to as ‘‘ground-glass opacity’’
(GGO).3 It has been shown that GGOs are more likely to
be an early form of adenocarcinomas, such as bronchioloal-
veolar carcinoma, adenocarcinoma in situ, or minimally in-
vasive adenocarcinoma. In particular, some GGOs are
accompanied by a solid part, and it has been demonstrated
that a solid component represents the portion of invasive
growth. These observations suggested that the degree of
pathologic invasive growth in adenocarcinoma could be
quantified according to the proportion of increased solid
density in the CT appearance of the lesion.9
On the basis of these observations, the JCOG 0201
study was planned to establish radiologic criteria that
could be used to identify pathologic early (noninvasive)
adenocarcinomas according to the quantification of the
solid component in TSCT. For this purpose, a consolida-
tion/tumor (C/T) ratio on TSCT was used, and the hypoth-
esis that a C/T ratio 0.50 or less in cT1a-b (3.0 cm) in
the TNM staging system (7th) indicates a noninvasive pa-
thology was tested with specificity as the primary end
point. The pathology-radiology correlation has been de-
scribed.8 The present study addresses the evaluation of
a radiologic criterion in terms of the prognosis after sur-
gery. If we can combine prognostic and pathologicThe Journal of Thoracic and Cfeatures, we may be able to improve the radiologic criteria
for defining noninvasive adenocarcinoma.PATIENTS AND METHODS
The Japan Clinical Oncology Group 0201 Study
The study design and primary results of the prospective, multi-
institutional study entitled JCOG 0201 have been published.8 The study
protocol was approved by the JCOG Clinical Trial Review Committee
and the institutional review board of each participating center. The study
was originally intended to define the radiologic criteria that indicate the
pathologic noninvasiveness of adenocarcinomas arising in the periphery
of the lung. If the radiologic selection of early adenocarcinomas with an
excellent prognosis could be achieved, candidates for limited resection,
not for lobectomy, could be precisely identified. Therefore, the radiologic
definition of noninvasive adenocarcinoma needs to be assessed not only ac-
cording to the radiology-pathology correlation but also according to the
prognosis. The current study describes the prognosis of patients with re-
sected adenocarcinoma according to different radiologic criteria. In brief,
patients who met the following criteria were enrolled in the JCOG 0201
study: (1) a suspected or diagnosed lung cancer based on the findings
from a plain x-ray or CT scan; (2) clinical stage IA (ie, T1N0M0) by tho-
racic enhanced CT; (3) the center of the tumor located peripherally (ie, in
the outer half of the lung field) on CT; (4) measurable in at least 1 dimen-
sion in TSCT; (5) age 20 to 75 years; (6) no prior thoracotomy; (7) feasible
for pulmonary lobectomy; and (8) obtained written informed consent.
Before surgery, all patients underwent a contrast-enhanced, thin-section
helical CT scan with 1- to 3-mm collimation, with particular focus on
the primary tumor to estimate the size of the entire tumor, including
GGO and the solid part (consolidation), where the C/T ratio was defined
as a predictor of pathologic early adenocarcinoma (Figure 1). The patients
then underwent surgical resection with at least lobectomy and hilar/medi-
astinal lymph node dissection. In the JCOG 0201 study, the appropriateness
of C/T ratios of 0.50 for cT1a-b (3.0 cm) and 0.25 for cT1a (2.0 cm) was
studied by comparing the C/T ratio and pathology of the resected specimen.
The primary end point of the studywas the specificity, which was defined as
the proportion of patients with radiologically diagnosed invasive lung
cancer determined by the central radiologic review among patients with
pathologically diagnosed invasive lung cancer. Pathologic noninvasiveness
was defined as pN0 disease with neither vascular invasion nor lymphatic
permeation on resected specimen.
Patients
Between December 2002 and May 2004, we enrolled 811 patients from
31 institutions. There were 357 men and 454 women (age range, 27-75
years; median, 61 years). Of these, 562 patients (69.3%) underwent major
lung resection. After 17 patients who were ineligible on the basis of post-
operative pathologic findings were excluded, the prognosis of 545 patients
(67.2%) was finally studied according to radiologic criteria for noninvasive
adenocarcinoma mainly represented by the C/T ratio. The subjects of this
study are the same as those in the analysis of pathology-radiology correla-
tion of JCOG0201.
Statistical Analysis
The method of sample size calculation has been described.8 Overall sur-
vival was defined as the duration from enrollment to death from any cause.
For the patients alive, overall survival was censored at the last visit.
Relapse-free survival was defined as the duration from enrollment to first
recurrence or death from any cause. For the patients alive and
recurrence-free, relapse-free survival was censored at the last visit. The
probability of survival was estimated by the Kaplan–Meier method, and
survival curves were drawn. The difference in survival between the groups
was tested by the log-rank test. All P values were 2-sided. All statisticalardiovascular Surgery c Volume 146, Number 1 25
FIGURE 1. Calculation of the C/T ratio to define radiologic noninvasive
lung cancer on TSCT. The maximum diameter of consolidation (C) is di-
vided by the maximum tumor diameter (T) to give the C/T ratio. GGO,
Ground-glass opacity; C/T, consolidation/tumor; TSCT, thin-section com-
puted tomography.
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Sanalyses were performedwith SAS software release 9.2 (SAS Institute, Inc,
Cary, NC) by the JCOG Data Center.FIGURE 2. Overall (A) and relapse-free (B) survival curves for the entire
group (cT1a-b,3.0 cm, n¼ 545).OS, Overall survival; RFS, relapse-free
survival.RESULTS
Prognosis of Patients According to a Consolidation/
Tumor Ratio 0.5 or Less (n ¼ 545)
The patient characteristics of the entire cT1a-b (3.0 cm)
population are shown in Table 1.Among the 545 patients, 233
(42.8%) were men and 312 (57.2%) were women. The me-
dian age was 62 years (range, 35-75 years). The median
follow-up period among overall patients was 7.1 years after
surgery (range, 0-8.6 years). The overall and relapse-freeTABLE 1. Patient characteristics of the entire cT1a-b (3.0 cm)
population (n ¼ 545)
Characteristics No. of patients (%)
Gender
Men 233 (42.8)
Women 312 (57.2)
Age (y)
Median (range) 62 (35-75)
Maximum tumor diameter on TSCT*
2.0 cm 289 (53.0)
>2.0-3.0 254 (46.6)
Unknown 2 (0.4)
C/T ratio on TSCT* and final pathologyy
0.5 (radiologically noninvasive) 121 (22.2)
Pathologically noninvasive 115 (21.1)
Pathologically invasive 6 (1.1)
>0.5 (radiologically invasive) 424 (77.8)
Pathologically noninvasive 263 (48.3)
Pathologically invasive 161 (29.5)
TSCT, Thin-section computed tomography; C/T, consolidation/tumor. *Maximum tu-
mor diameter and a C/T ratio on TSCT were both evaluated by a central radiologic
review board. yPatients with adenocarcinoma that was diagnosed at the time of sur-
gery were eligible, and 16 patients with a different final pathologic diagnosis were in-
cluded in the pathologically invasive group.
26 The Journal of Thoracic and Cardiovascular Surgesurvival curves of the cT1a-b (3.0 cm) population are pre-
sented in Figure 2, and the 5-year overall and relapse-free
survivals were 90.6% and 84.7%, respectively. Among the
545 adenocarcinomas, when a C/T ratio 0.5 or less in
cT1a-b (3.0 cm) was used as a radiologic criterion for non-
invasive cancer, 121 adenocarcinomas (22.2%) were diag-
nosed as noninvasive and 424 adenocarcinomas (77.8%)
were diagnosed as invasive. Among the 121 radiologic non-
invasive adenocarcinomas, 115 (95.0%) were precisely de-
termined to be pathologic noninvasive cancer. Among the
424 radiologic invasive adenocarcinomas, 161 (38.0%)
were precisely determined to be pathologic invasive cancer.
Therefore, the specificity and sensitivity were 96.4% (95%
confidence interval [CI], 92.3-98.7) and 30.4% (95% CI,
25.8-35.3), respectively. The overall survival curves for ra-
diologic noninvasive cancer (n ¼ 121) and invasive cancer
(n ¼ 424) are presented in Figure 3, A. The 5-year overall
survivals for noninvasive cancer and invasive cancer were
96.7% and 88.9%, respectively, and the difference in overall
survival was statistically significant (P<.001). The relapse-
free survival curves for radiologic noninvasive cancer
(n ¼ 121) and invasive cancer (n ¼ 424) are presented in
Figure 3, B. The 5-year relapse-free survivals for noninvasive
and invasive cancer were 95.9% and 81.6%, respectively,
and the difference in relapse-free survival was statistically
significant (P<.001).ry c July 2013
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FIGURE 3. Overall (A) and relapse-free (B) survival curves for radiolog-
ically noninvasive (n ¼ 121) and invasive (n ¼ 424) adenocarcinomas
based on a C/T ratio of 0.50 or less in cT1a-b (3.0 cm) for noninvasive-
ness on TSCT. The differences in overall and relapse-free survival are sta-
tistically significant (P < .001 and < .001, respectively). OS, Overall
survival; RFS, relapse-free survival; C/T, consolidation/tumor; TSCT,
thin-section computed tomography.
TABLE 2. Patient characteristics of cT1a (2.0 cm) population
(n ¼ 289)
Characteristics No. of patients (%)
Gender
Men 129 (44.6)
Women 160 (55.4)
Age (y)
Median (range) 61 (35-75)
C/T ratio on TSCT* and final pathologyy
0.25 (radiologically noninvasive) 35 (12.1)
Pathologically noninvasive 34 (11.8)
Pathologically invasive 1 (0.3)
>0.25 (radiologically invasive) 254 (87.9)
Pathologically noninvasive 176 (60.9)
Pathologically invasive 78 (27.0)
C/T, Consolidation/tumor; TSCT, thin-section computed tomography. *Maximum tu-
mor diameter and a C/T ratio on TSCT were both evaluated by a central radiologic
review board. yPatients with adenocarcinoma that was diagnosed at the time of sur-
gery were eligible, and the patients with a different final pathologic diagnosis were
included in the pathologically invasive group.
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SPrognosis of Patients According to a Consolidation/
Tumor Ratio 0.25 or Less for cT1a Adenocarcinomas
(2.0 cm in Size) (n ¼ 289)
The patient characteristics of this population are shown in
Table 2. Among the 289 patients, 129 (44.6%) were men
and 160 (55.4%) were women. The median age was 61
years (range, 35-75 years). The median follow-up period
among overall patients was 7.1 years after surgery (range,
0-8.5 years). The overall and relapse-free survival curves
for the cT1a (2.0 cm) population (n ¼ 289) are presented
in Figure 4, and the 5-year overall and relapse-free survivals
were 93.0% and 88.9%, respectively. Among the 289 cT1a
(2.0 cm) adenocarcinomas, when a C/T ratio 0.25 or less
was used as a radiologic criterion for noninvasive cancer, 35
adenocarcinomas (12.1%) were diagnosed as noninvasive
and 254 adenocarcinomas (87.9%) were diagnosed as inva-
sive. Among the 35 radiologic noninvasive adenocarci-
nomas, 34 (97.1%) were precisely determined to be
pathologic noninvasive cancer. Among the 254 radiologic
invasive adenocarcinomas, 78 (30.7%) were precisely de-
termined to be pathologic invasive cancer. Therefore, theThe Journal of Thoracic and Cspecificity and sensitivity were 98.7% (95% CI, 93.2-
100.0) and 16.2% (95% CI, 11.5-21.9), respectively. The
overall survival curves for radiologic noninvasive cancer
(n ¼ 35) and invasive cancer (n ¼ 254) are presented in
Figure 5, A. The 5-year overall survivals for noninvasive
cancer and invasive cancer were 97.1% and 92.4%, respec-
tively, and the difference in overall survival was not statis-
tically significant (P ¼ .259). The relapse-free survival
curves for radiologic noninvasive cancer (n ¼ 35) and inva-
sive cancer (n ¼ 254) are presented in Figure 5, B. The
5-year relapse-free survivals for noninvasive and invasive
cancer were 97.1% and 87.7%, respectively, and the differ-
ence in relapse-free survival was not statistically significant
(P ¼ .106).Prognosis of Patients With cT1b Adenocarcinomas
(>2.0-3.0 cm in Size) (n ¼ 254) According to
a Consolidation/Tumor Ratio 0.5 or Less
Two patients with unknown preoperative tumor size were
excluded. Among the 254 patients, 104 (40.9%) were men
and 150 (59.1%) werewomen. The median age was 62 years
(range, 37-75 years). The median follow-up period among
overall patients was 7.0 years after surgery (range, 0-8.5
years). The overall and relapse-free survivals for the cT1b
(>2.0-3.0 cm) population were 87.8% and 79.9%, respec-
tively. When a C/T ratio 0.5 or less was used as a radiologic
criterion for noninvasive cancer, 54 adenocarcinomas
(21.3%) were diagnosed as noninvasive and 200 adenocarci-
nomas (78.7%) were diagnosed as invasive. The overall sur-
vival curves for radiologic noninvasive cancer (n ¼ 54) and
invasive cancer (n ¼ 200) are presented in Figure 6, A. The
5-year overall survivals for noninvasive cancer and invasive
cancer were 96.3% and 85.5%, respectively, and the differ-
ence in overall survival was statistically significantardiovascular Surgery c Volume 146, Number 1 27
FIGURE 4. Overall (A) and relapse-free (B) survival curves for the cT1a
(2.0 cm) group (n ¼ 289). OS, Overall survival; RFS, relapse-free
survival.
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FIGURE 5. Overall (A) and relapse-free (B) survival curves for radiolog-
ically noninvasive (n¼ 35) and invasive (n¼ 254) adenocarcinomas based
on a C/T ratio of 0.25 or less in cT1a (2.0 cm) for noninvasiveness on
TSCT. The differences in overall and relapse-free survival are not statisti-
cally significant (P ¼ .259 and .106, respectively). OS, Overall survival;
RFS, relapse-free survival; C/T, consolidation/tumor; TSCT, thin-section
computed tomography.
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noninvasive cancer (n ¼ 54) and invasive cancer (n ¼ 200)
are presented in Figure 6,B. The 5-year relapse-free survivals
for noninvasive and invasive cancer were 94.4% and 76.0%,
respectively, and the difference in relapse-free survival was
statistically significant (P ¼ .003).
DISCUSSION
During the past 80 years, the surgical mode of pulmonary
resection for lung cancer has evolved from pneumonectomy
to lobectomy.10,11 Currently, resection of the entire tumor-
bearing lobe is being adopted as the standard mode of sur-
gical resection for lung cancer. During this period, attempts
have been made to minimize the resection through lobec-
tomy to limited sublobar resection. Most importantly, the
NorthAmerican LungCancer StudyGroup conducted a pro-
spective, randomized trial that compared limited resection
with lobectomy for stage I lung cancer.12 The principal find-
ing in that study was a 3-fold increase in local recurrence
(17.2% vs 6.4%) in patients who had sublobar resection
and a 2.4-fold increase in those with segmental resection.
A 30% increase in the overall death rate and a 50% increase
in the rate of death with cancer in patients with limited re-
section were also observed compared with those with lobec-
tomy. Therefore, it was concluded that lobectomy should28 The Journal of Thoracic and Cardiovascular Surgestill be considered the surgical procedure of choice for pe-
ripheral T1N0 non–small cell lung cancer. However,
present-day critiques of this study are arising with regard
to the marginal prognostic significance, poor preoperative
workup for metastasis, slow accrual rate of the study, ab-
sence of data on pulmonary function (no demonstration of
superiority in pulmonary function for lesser resection),
and the notion that this study is outdated.
Despite the results of the North American Lung Cancer
Study Group study, many nonrandomized studies have been
published, and their results suggested that an equivalent prog-
nosis could be achieved with limited sublobar resection for
selected non–small cell lung cancer as with lobectomy.13-18
Especially for earlier forms of noninvasive or minimally
invasive adenocarcinoma such as bronchioloalveolar
carcinoma, it has been shown that these cases present with
a GGO appearance on TSCT and could be treated with
limited sublobar resections, such as wide wedge resection
and segmentectomy.13-18 Because of the accumulation of
excellent prognoses by limited resection in nonrandomized
studies, surgeons require a fair comparison of lobectomyry c July 2013
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FIGURE 6. Overall (A) and relapse-free (B) survival curves for radiolog-
ically noninvasive (n¼ 54) and invasive (n¼ 200) adenocarcinomas based
on a C/T ratio 0.5 in cT1b (>2.0-3.0 cm) for noninvasiveness on TSCT.
The differences in overall and relapse-free survival are statistically
significant (P ¼ .003 and .003, respectively). OS, Overall survival; RFS,
relapse-free survival; C/T, consolidation/tumor; TSCT, thin-section com-
puted tomography.
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criteria for patient selection.
The radiologic criteria for noninvasive adenocarcinoma
need to be evaluated by both pathologic and prognostic
aspects. The radiology-pathology correlation has been stud-
ied in detail in JCOG0201, and the results have been pub-
lished.8 Briefly, JCOG 0201 failed to demonstrate that
a C/T ratio 0.5 or less in T1a-b is precisely predictive of
pathologic noninvasiveness. The specificity and sensitivity
for these criteria were 96.4% (95% CI, 92.3-98.7) and
30.4% (95% CI, 25.8-35.3), respectively, and they did
not reach the hypotheses in the JCOG 0201 study that the
lower limit for 95% CI of specificity exceeds 97%. How-
ever, according to an exploratory study, a C/T ratio 0.25
or less in cT1a (2.0 cm) showed a specificity of 98.7%
and a sensitivity of 16.2%, which was more precise for in-
dicating noninvasive pathologic features. On the basis of
these results, we recognized that a C/T ratio 0.25 or less
in cT1a (2.0 cm) on TSCT is a better indicator of a nonin-
vasive histology as early adenocarcinoma than a C/T ratio
0.50 or less in cT1a-b (3.0 cm). In this additional studyThe Journal of Thoracic and Cof JCOG 0201, we looked at the prognoses obtained by
these 2 radiologic criteria and focused on whether noninva-
sive adenocarcinomas defined by these 2 criteria could indi-
cate a good prognosis as early adenocarcinoma.
In contrast to the results regarding the radiology-
pathology correlation in the JCOG 0201 study, superb prog-
noses were obtained for noninvasive adenocarcinomas
according to both of these criteria: The 5-year overall sur-
vivals for a C/T ratio 0.50 or less in cT1a-b (3.0 cm)
and a C/T ratio 0.25 or less in cT1a (2.0 cm) were
96.7% and 97.1%, respectively. Although our previous re-
port stated that a C/T ratio 0.25 or less in cT1a (2.0 cm)
was an appropriate indicator to select patients with noninva-
sive lung adenocarcinomas suitable for limited sublobar re-
section,8 these results indicate that even with a generous
radiologic criterion on TSCT (a C/T ratio 0.50 in
cT1a-b), we can precisely select a group of patients with
early adenocarcinomas who have an excellent prognosis.
For these patients, it is considered that limited sublobar re-
section achieves a prognosis that is almost the same as that
with lobectomy and a better preservation of the lung paren-
chyma. In terms of the postoperative prognosis, this analy-
sis indicates that noninvasive adenocarcinomas can be
properly selected on TSCT using radiologic criteria of
a C/T ratio of 0.50 or 0.25.
There is a caution regarding the excellent prognoses of
the patients with noninvasive adenocarcinomas in this
study. Patients included in the JCOG 0201 study underwent
lobectomy and hilar/mediastinal lymph node dissection,
which is usually indicated for any type of resectable lung
cancer as a radical resection. The prognoses in this study
were achieved by such radical resection; therefore,
the same prognoses are not warranted for these tumors if
they are resected with limited sublobar resections, although
this was suggested by previous studies with case series.13-18
We should still be prudent in addressing the excellent
prognoses of early adenocarcinomas with surgical
resection other than lobectomy.
On the basis of these results, 2 prospective, collaborative
studies between JCOG and the West Japan Oncology
Group, JCOG0804/WJOG4507L (UMIN-CTR [www.
umin.ac.jp/ctr/] No. UMIN000002008) and JCOG0802/
WJOG4607L (UMIN-CTR No.UMIN000002317), are un-
der way on peripherally located adenocarcinomas of the
lung.19 In these studies, a radiologic criterion of a C/T ratio
0.25 or less in cT1a is used to define noninvasive adenocar-
cinomas. For radiologic noninvasive adenocarcinomas with
a tumor diameter of 2 cm or less, a phase II study with 1 ex-
perimental arm (JCOG0804/WJOG4507L) is under way in
which tumors are resected with a wide wedge resection. As
of March 2012, the target number of accrual (330 patients)
was reached, and maturation of follow-up data on recur-
rence and prognosis is awaited. For radiologic invasive ad-
enocarcinomas with a tumor diameter 2.0 cm or less andardiovascular Surgery c Volume 146, Number 1 29
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phase III study (JCOG0802/WJOG4607L) between lobec-
tomy and segmentectomy in a noninferiority setting is un-
der way. The primary and key secondary end points are
overall survival and postoperative pulmonary function, re-
spectively. If the prognosis of those undergoing segmentec-
tomy is not inferior to that of those undergoing lobectomy
and the pulmonary function of those undergoing segmen-
tectomy is significantly better than that of those undergoing
lobectomy, we will conclude that segmentectomy should be
the standard mode of pulmonary resection for a peripherally
located radiologic invasive adenocarcinomawith a diameter
of 2.0 cm or less and a C/T ratio greater than 0.25. The target
number of patients is 1100, and accrual is under way. This
study will clarify the pathologic and survival outcomes of
the patients with cT1a (2.0 cm) tumor and a C/T ratio
ranging from 0.25 to 0.5, and might validate the radiologic
definition of a C/T ratio 0.5 or less for noninvasive lung ad-
enocarcinoma among the cT1a (2.0 cm) group. In North
America, a similar study entitled Cancer and Leukemia
Group B 140503 is also under way, in which the prognosis
and preservation of pulmonary function is compared be-
tween lobectomy and limited resection in a noninferiority
setting.20,21 The current survival analysis showed that
noninvasive adenocarcinomas indicative of limited
resection could be selected by the size of 3 cm or less and
a C/T ratio 0.5 or less. Even the patients with cT1b tumors
(>2-3 cm) may be candidates for limited resection if their
preoperative C/T ratio is 0.5 or less. For cT1b tumors,
segmentectomy but not wide wedge resection should be
considered as an appropriate limited resection to obtain
adequate surgical margins. Future prospective study will
be needed to investigate the clinical significance of
intentional segmentectomy for such a population.
CONCLUSIONS
Despite the finding that a noninvasive pathology is better
predicted with a C/T ratio 0.25 or less on TSCT in cT1a
(2.0 cm) than with 0.50 or less in cT1a-b (3.0 cm),
both of these radiologic criteria could identify a group of pa-
tients with an excellent prognosis, with a 5-year overall sur-
vival of approximately 97%. These criteria can be used to
select patients with peripherally located adenocarcinomas
in whom a limited resection, such as wide wedge resection
or segmentectomy, might be safely indicated.
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